Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
ACAD Stock Chart & Stats
$23.22
-$0.09(-0.52%)
At close: 4:00 PM EST
$23.22
-$0.09(-0.52%)
Day’s Range― - ―
52-Week Range$13.40 - $28.35
Previous CloseN/A
Volume443.16K
Average Volume (3M)1.21M
Market Cap
$3.99B
Enterprise Value$3.73B
Total Cash (Recent Filing)$847.02M
Total Debt (Recent Filing)$54.81M
Price to Earnings (P/E)14.9
Beta1.07
Next Earnings
Feb 25, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.42
Shares Outstanding169,181,820
10 Day Avg. Volume1,359,539
30 Day Avg. Volume1,208,931
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)4.15
Price to Sales (P/S)3.17
P/FCF Ratio19.34
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue3.56
Enterprise Value/Gross Profit3.87
Enterprise Value/Ebitda31.76
Forecast
1Y Price Target
$31.17Price Target Upside34.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial MomentumAnalyst notes growing commercial momentum for Nuplazid and Daybue driven by an expanded field force and direct-to-consumer campaigns that support higher new prescriptions and improved treatment persistence.
Formulation UpgradeApproval and rollout of DAYBUE STIX powder-for-oral-solution is expected to expand patient access and improve tolerability by addressing swallowing, taste, and gastrointestinal barriers.
Pipeline Clinical CatalystsUpcoming late-stage readouts for ACP-204 and remlifanserin provide meaningful upside optionality, with potential clinically meaningful results that could re-rate the pipeline beyond the current marketed products.
Bears Say
European Regulatory SetbackA negative CHMP trend vote on the marketing application for trofinetide creates regulatory uncertainty in Europe and reduces the likelihood and timing of European revenue contribution.
Re-examination And Timeline RiskPursuit of a formal re-examination process implies delays and prolonged uncertainty for European approval, prompting analysts to assume a more cautious outlook until regulatory clarity is achieved.
Sales Visibility And Community UptakeReliance on specialty pharmacies and third-party prescription sources limits sales data visibility, and slower prescribing by community physicians may constrain broader uptake outside specialty settings.
ACADIA Pharmaceuticals News
ACAD FAQ
What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest stock price was $13.40 and its highest was $28.35 in the past 12 months.
What is ACADIA Pharmaceuticals’s market cap?
ACADIA Pharmaceuticals’s market cap is $3.99B.
When is ACADIA Pharmaceuticals’s upcoming earnings report date?
ACADIA Pharmaceuticals’s upcoming earnings report date is Feb 25, 2026 which is in 14 days.
How were ACADIA Pharmaceuticals’s earnings last quarter?
ACADIA Pharmaceuticals released its earnings results on Nov 05, 2025. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.173 by $0.247.
Is ACADIA Pharmaceuticals overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued.
Does ACADIA Pharmaceuticals pay dividends?
ACADIA Pharmaceuticals does not currently pay dividends.
What is ACADIA Pharmaceuticals’s EPS estimate?
ACADIA Pharmaceuticals’s EPS estimate is 0.13.
How many shares outstanding does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has 169,181,820 shares outstanding.
What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
ACADIA Pharmaceuticals reported an EPS of $0.42 in its last earnings report, beating expectations of $0.173. Following the earnings report the stock price went down -3.045%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
Currently, no hedge funds are holding shares in ACAD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ACADIA Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$31.17 (34.24% Upside)
$31.17 (34.24% Upside)
Blogger Sentiment
Bullish
ACAD Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 64.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $670.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 12.0%
Last 30 Days ▼ 12.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.17%
12-Months-Change
Fundamentals
Return on Equity
34.95%
Trailing 12-Months
Asset Growth
36.23%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
ACAD Company Deck
ACAD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with robust revenue growth and strategic investments in DAYBUE and NUPLAZID, alongside pipeline advancements. However, challenges persist with DAYBUE's market penetration and increased R&D expenses.View all ACAD earnings summariesACAD Stock 12 Month Forecast
Average Price Target
$31.17
▲(34.24% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
PTC Therapeutics
―
Krystal Biotech
―
MoonLake Immunotherapeutics
―
Arcellx Inc
―
Ownership Overview
Currently, No data available
---